Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 11 of 11 entries
Sorted by: Best Match Show Resources per page
Cytokeratin on frozen sections of sentinel node may spare breast cancer patients secondary axillary surgery.

Pathology research international

Stovgaard ES, Tvedskov TF, Lænkholm AV, Balslev E.
PMID: 22655220
Patholog Res Int. 2012;2012:802184. doi: 10.1155/2012/802184. Epub 2012 May 09.

Background. The feasibility and accuracy of immunohistochemistry (IHC) on frozen sections, when assessing sentinel node (SN) status intraoperatively in breast cancer, is a matter of continuing discussion. In this study, we compared a center using IHC on frozen section...

Cite
Stovgaard ES, Tvedskov TF, Lænkholm AV, et al. Cytokeratin on frozen sections of sentinel node may spare breast cancer patients secondary axillary surgery. Patholog Res Int. 2012;2012:802184doi: 10.1155/2012/802184.
Stovgaard, E. S., Tvedskov, T. F., Lænkholm, A. V., & Balslev, E. (2012). Cytokeratin on frozen sections of sentinel node may spare breast cancer patients secondary axillary surgery. Pathology research international, 2012802184. https://doi.org/10.1155/2012/802184
Stovgaard, Elisabeth Specht, et al. "Cytokeratin on frozen sections of sentinel node may spare breast cancer patients secondary axillary surgery." Pathology research international vol. 2012 (2012): 802184. doi: https://doi.org/10.1155/2012/802184
Stovgaard ES, Tvedskov TF, Lænkholm AV, Balslev E. Cytokeratin on frozen sections of sentinel node may spare breast cancer patients secondary axillary surgery. Patholog Res Int. 2012;2012:802184. doi: 10.1155/2012/802184. Epub 2012 May 09. PMID: 22655220; PMCID: PMC3357584.
Copy Download .nbib Format: NLM
Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group.

Journal of the National Cancer Institute

Nielsen TO, Leung SCY, Rimm DL, Dodson A, Acs B, Badve S, Denkert C, Ellis MJ, Fineberg S, Flowers M, Kreipe HH, Laenkholm AV, Pan H, Penault-Llorca FM, Polley MY, Salgado R, Smith IE, Sugie T, Bartlett JMS, McShane LM, Dowsett M, Hayes DF.
PMID: 33369635
J Natl Cancer Inst. 2021 Jul 01;113(7):808-819. doi: 10.1093/jnci/djaa201.

Ki67 immunohistochemistry (IHC), commonly used as a proliferation marker in breast cancer, has limited value for treatment decisions due to questionable analytical validity. The International Ki67 in Breast Cancer Working Group (IKWG) consensus meeting, held in October 2019, assessed...

Cite
Nielsen TO, Leung SCY, Rimm DL, et al. Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group. J Natl Cancer Inst. 2021;113(7):808-819doi: 10.1093/jnci/djaa201.
Nielsen, T. O., Leung, S. C. Y., Rimm, D. L., Dodson, A., Acs, B., Badve, S., Denkert, C., Ellis, M. J., Fineberg, S., Flowers, M., Kreipe, H. H., Laenkholm, A. V., Pan, H., Penault-Llorca, F. M., Polley, M. Y., Salgado, R., Smith, I. E., Sugie, T., Bartlett, J. M. S., McShane, L. M., Dowsett, M., & Hayes, D. F. (2021). Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group. Journal of the National Cancer Institute, 113(7), 808-819. https://doi.org/10.1093/jnci/djaa201
Nielsen, Torsten O, et al. "Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group." Journal of the National Cancer Institute vol. 113,7 (2021): 808-819. doi: https://doi.org/10.1093/jnci/djaa201
Nielsen TO, Leung SCY, Rimm DL, Dodson A, Acs B, Badve S, Denkert C, Ellis MJ, Fineberg S, Flowers M, Kreipe HH, Laenkholm AV, Pan H, Penault-Llorca FM, Polley MY, Salgado R, Smith IE, Sugie T, Bartlett JMS, McShane LM, Dowsett M, Hayes DF. Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group. J Natl Cancer Inst. 2021 Jul 01;113(7):808-819. doi: 10.1093/jnci/djaa201. PMID: 33369635; PMCID: PMC8487652.
Copy Download .nbib Format: NLM
Correction: Gene expression profiling identifies FYN as an important molecule in tamoxifen resistance and a predictor of early recurrence in patients treated with endocrine therapy.

Oncogene

Elias D, Vever H, Lænkholm AV, Gjerstorff MF, Yde CW, Lykkesfeldt AE, Ditzel HJ.
PMID: 31712727
Oncogene. 2020 Mar;39(10):2229-2230. doi: 10.1038/s41388-019-1096-8.

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Cite
Elias D, Vever H, Lænkholm AV, et al. Correction: Gene expression profiling identifies FYN as an important molecule in tamoxifen resistance and a predictor of early recurrence in patients treated with endocrine therapy. Oncogene. 2020;39(10):2229-2230doi: 10.1038/s41388-019-1096-8.
Elias, D., Vever, H., Lænkholm, A. V., Gjerstorff, M. F., Yde, C. W., Lykkesfeldt, A. E., & Ditzel, H. J. (2020). Correction: Gene expression profiling identifies FYN as an important molecule in tamoxifen resistance and a predictor of early recurrence in patients treated with endocrine therapy. Oncogene, 39(10), 2229-2230. https://doi.org/10.1038/s41388-019-1096-8
Elias, D, et al. "Correction: Gene expression profiling identifies FYN as an important molecule in tamoxifen resistance and a predictor of early recurrence in patients treated with endocrine therapy." Oncogene vol. 39,10 (2020): 2229-2230. doi: https://doi.org/10.1038/s41388-019-1096-8
Elias D, Vever H, Lænkholm AV, Gjerstorff MF, Yde CW, Lykkesfeldt AE, Ditzel HJ. Correction: Gene expression profiling identifies FYN as an important molecule in tamoxifen resistance and a predictor of early recurrence in patients treated with endocrine therapy. Oncogene. 2020 Mar;39(10):2229-2230. doi: 10.1038/s41388-019-1096-8. PMID: 31712727; PMCID: PMC7056636.
Copy Download .nbib Format: NLM
Intra-Tumour Heterogeneity Is One of the Main Sources of Inter-Observer Variation in Scoring Stromal Tumour Infiltrating Lymphocytes in Triple Negative Breast Cancer.

Cancers

Kilmartin D, O'Loughlin M, Andreu X, Bagó-Horváth Z, Bianchi S, Chmielik E, Cserni G, Figueiredo P, Floris G, Foschini MP, Kovács A, Heikkilä P, Kulka J, Laenkholm AV, Liepniece-Karele I, Marchiò C, Provenzano E, Regitnig P, Reiner A, Ryška A, Sapino A, Specht Stovgaard E, Quinn C, Zolota V, Webber M, Roshan D, Glynn SA, Callagy G.
PMID: 34503219
Cancers (Basel). 2021 Aug 31;13(17). doi: 10.3390/cancers13174410.

Stromal tumour infiltrating lymphocytes (sTILs) are a strong prognostic marker in triple negative breast cancer (TNBC). Consistency scoring sTILs is good and was excellent when an internet-based scoring aid developed by the TIL-WG was used to score cases in...

Cite
Kilmartin D, O'Loughlin M, Andreu X, et al. Intra-Tumour Heterogeneity Is One of the Main Sources of Inter-Observer Variation in Scoring Stromal Tumour Infiltrating Lymphocytes in Triple Negative Breast Cancer. Cancers (Basel). 2021;13(17)doi: 10.3390/cancers13174410.
Kilmartin, D., O'Loughlin, M., Andreu, X., Bagó-Horváth, Z., Bianchi, S., Chmielik, E., Cserni, G., Figueiredo, P., Floris, G., Foschini, M. P., Kovács, A., Heikkilä, P., Kulka, J., Laenkholm, A. V., Liepniece-Karele, I., Marchiò, C., Provenzano, E., Regitnig, P., Reiner, A., Ryška, A., Sapino, A., Specht Stovgaard, E., Quinn, C., Zolota, V., Webber, M., Roshan, D., Glynn, S. A., & Callagy, G. (2021). Intra-Tumour Heterogeneity Is One of the Main Sources of Inter-Observer Variation in Scoring Stromal Tumour Infiltrating Lymphocytes in Triple Negative Breast Cancer. Cancers, 13(17), . https://doi.org/10.3390/cancers13174410
Kilmartin, Darren, et al. "Intra-Tumour Heterogeneity Is One of the Main Sources of Inter-Observer Variation in Scoring Stromal Tumour Infiltrating Lymphocytes in Triple Negative Breast Cancer." Cancers vol. 13,17 (2021). doi: https://doi.org/10.3390/cancers13174410
Kilmartin D, O'Loughlin M, Andreu X, Bagó-Horváth Z, Bianchi S, Chmielik E, Cserni G, Figueiredo P, Floris G, Foschini MP, Kovács A, Heikkilä P, Kulka J, Laenkholm AV, Liepniece-Karele I, Marchiò C, Provenzano E, Regitnig P, Reiner A, Ryška A, Sapino A, Specht Stovgaard E, Quinn C, Zolota V, Webber M, Roshan D, Glynn SA, Callagy G. Intra-Tumour Heterogeneity Is One of the Main Sources of Inter-Observer Variation in Scoring Stromal Tumour Infiltrating Lymphocytes in Triple Negative Breast Cancer. Cancers (Basel). 2021 Aug 31;13(17). doi: 10.3390/cancers13174410. PMID: 34503219; PMCID: PMC8431498.
Copy Download .nbib Format: NLM
Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer.

NPJ breast cancer

Kos Z, Roblin E, Kim RS, Michiels S, Gallas BD, Chen W, van de Vijver KK, Goel S, Adams S, Demaria S, Viale G, Nielsen TO, Badve SS, Symmans WF, Sotiriou C, Rimm DL, Hewitt S, Denkert C, Loibl S, Luen SJ, Bartlett JMS, Savas P, Pruneri G, Dillon DA, Cheang MCU, Tutt A, Hall JA, Kok M, Horlings HM, Madabhushi A, van der Laak J, Ciompi F, Laenkholm AV, Bellolio E, Gruosso T, Fox SB, Araya JC, Floris G, Hudeček J, Voorwerk L, Beck AH, Kerner J, Larsimont D, Declercq S, Van den Eynden G, Pusztai L, Ehinger A, Yang W, AbdulJabbar K, Yuan Y, Singh R, Hiley C, Bakir MA, Lazar AJ, Naber S, Wienert S, Castillo M, Curigliano G, Dieci MV, André F, Swanton C, Reis-Filho J, Sparano J, Balslev E, Chen IC, Stovgaard EIS, Pogue-Geile K, Blenman KRM, Penault-Llorca F, Schnitt S, Lakhani SR, Vincent-Salomon A, Rojo F, Braybrooke JP, Hanna MG, Soler-Monsó MT, Bethmann D, Castaneda CA, Willard-Gallo K, Sharma A, Lien HC, Fineberg S, Thagaard J, Comerma L, Gonzalez-Ericsson P, Brogi E, Loi S, Saltz J, Klaushen F, Cooper L, Amgad M, Moore DA, Salgado R.
PMID: 32411819
NPJ Breast Cancer. 2020 May 12;6:17. doi: 10.1038/s41523-020-0156-0. eCollection 2020.

Stromal tumor-infiltrating lymphocytes (sTILs) are important prognostic and predictive biomarkers in triple-negative (TNBC) and HER2-positive breast cancer. Incorporating sTILs into clinical practice necessitates reproducible assessment. Previously developed standardized scoring guidelines have been widely embraced by the clinical and research...

Cite
Kos Z, Roblin E, Kim RS, et al. Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. NPJ Breast Cancer. 2020;6:17doi: 10.1038/s41523-020-0156-0.
Kos, Z., Roblin, E., Kim, R. S., Michiels, S., Gallas, B. D., Chen, W., van de Vijver, K. K., Goel, S., Adams, S., Demaria, S., Viale, G., Nielsen, T. O., Badve, S. S., Symmans, W. F., Sotiriou, C., Rimm, D. L., Hewitt, S., Denkert, C., Loibl, S., Luen, S. J., Bartlett, J. M. S., Savas, P., Pruneri, G., Dillon, D. A., Cheang, M. C. U., Tutt, A., Hall, J. A., Kok, M., Horlings, H. M., Madabhushi, A., van der Laak, J., Ciompi, F., Laenkholm, A. V., Bellolio, E., Gruosso, T., Fox, S. B., Araya, J. C., Floris, G., Hudeček, J., Voorwerk, L., Beck, A. H., Kerner, J., Larsimont, D., Declercq, S., Van den Eynden, G., Pusztai, L., Ehinger, A., Yang, W., AbdulJabbar, K., Yuan, Y., Singh, R., Hiley, C., Bakir, M. A., Lazar, A. J., Naber, S., Wienert, S., Castillo, M., Curigliano, G., Dieci, M. V., André, F., Swanton, C., Reis-Filho, J., Sparano, J., Balslev, E., Chen, I. C., Stovgaard, E. I. S., Pogue-Geile, K., Blenman, K. R. M., Penault-Llorca, F., Schnitt, S., Lakhani, S. R., Vincent-Salomon, A., Rojo, F., Braybrooke, J. P., Hanna, M. G., Soler-Monsó, M. T., Bethmann, D., Castaneda, C. A., Willard-Gallo, K., Sharma, A., Lien, H. C., Fineberg, S., Thagaard, J., Comerma, L., Gonzalez-Ericsson, P., Brogi, E., Loi, S., Saltz, J., Klaushen, F., Cooper, L., Amgad, M., Moore, D. A., Salgado, R. (2020). Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. NPJ breast cancer, 617. https://doi.org/10.1038/s41523-020-0156-0
Kos, Zuzana, et al. "Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer." NPJ breast cancer vol. 6 (2020): 17. doi: https://doi.org/10.1038/s41523-020-0156-0
Kos Z, Roblin E, Kim RS, Michiels S, Gallas BD, Chen W, van de Vijver KK, Goel S, Adams S, Demaria S, Viale G, Nielsen TO, Badve SS, Symmans WF, Sotiriou C, Rimm DL, Hewitt S, Denkert C, Loibl S, Luen SJ, Bartlett JMS, Savas P, Pruneri G, Dillon DA, Cheang MCU, Tutt A, Hall JA, Kok M, Horlings HM, Madabhushi A, van der Laak J, Ciompi F, Laenkholm AV, Bellolio E, Gruosso T, Fox SB, Araya JC, Floris G, Hudeček J, Voorwerk L, Beck AH, Kerner J, Larsimont D, Declercq S, Van den Eynden G, Pusztai L, Ehinger A, Yang W, AbdulJabbar K, Yuan Y, Singh R, Hiley C, Bakir MA, Lazar AJ, Naber S, Wienert S, Castillo M, Curigliano G, Dieci MV, André F, Swanton C, Reis-Filho J, Sparano J, Balslev E, Chen IC, Stovgaard EIS, Pogue-Geile K, Blenman KRM, Penault-Llorca F, Schnitt S, Lakhani SR, Vincent-Salomon A, Rojo F, Braybrooke JP, Hanna MG, Soler-Monsó MT, Bethmann D, Castaneda CA, Willard-Gallo K, Sharma A, Lien HC, Fineberg S, Thagaard J, Comerma L, Gonzalez-Ericsson P, Brogi E, Loi S, Saltz J, Klaushen F, Cooper L, Amgad M, Moore DA, Salgado R. Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. NPJ Breast Cancer. 2020 May 12;6:17. doi: 10.1038/s41523-020-0156-0. eCollection 2020. PMID: 32411819; PMCID: PMC7217863.
Copy Download .nbib Format: NLM
The Prosigna 50-gene profile and responsiveness to adjuvant anthracycline-based chemotherapy in high-risk breast cancer patients.

NPJ breast cancer

Jensen MB, Lænkholm AV, Balslev E, Buckingham W, Ferree S, Glavicic V, Dupont Jensen J, Søegaard Knoop A, Mouridsen HT, Nielsen D, Nielsen TO, Ejlertsen B.
PMID: 32140564
NPJ Breast Cancer. 2020 Feb 26;6:7. doi: 10.1038/s41523-020-0148-0. eCollection 2020.

The DBCG89D trial randomized high-risk early breast cancer patients to adjuvant CMF (cyclophosphamide, methotrexate and fluorouracil) or CEF (cyclophosphamide, epirubicin and fluorouracil). Prosigna assays were performed by researchers with no access to clinical data. Time to distant recurrence (DR)...

Cite
Jensen MB, Lænkholm AV, Balslev E, et al. The Prosigna 50-gene profile and responsiveness to adjuvant anthracycline-based chemotherapy in high-risk breast cancer patients. NPJ Breast Cancer. 2020;6:7doi: 10.1038/s41523-020-0148-0.
Jensen, M. B., Lænkholm, A. V., Balslev, E., Buckingham, W., Ferree, S., Glavicic, V., Dupont Jensen, J., Søegaard Knoop, A., Mouridsen, H. T., Nielsen, D., Nielsen, T. O., & Ejlertsen, B. (2020). The Prosigna 50-gene profile and responsiveness to adjuvant anthracycline-based chemotherapy in high-risk breast cancer patients. NPJ breast cancer, 67. https://doi.org/10.1038/s41523-020-0148-0
Jensen, Maj-Britt, et al. "The Prosigna 50-gene profile and responsiveness to adjuvant anthracycline-based chemotherapy in high-risk breast cancer patients." NPJ breast cancer vol. 6 (2020): 7. doi: https://doi.org/10.1038/s41523-020-0148-0
Jensen MB, Lænkholm AV, Balslev E, Buckingham W, Ferree S, Glavicic V, Dupont Jensen J, Søegaard Knoop A, Mouridsen HT, Nielsen D, Nielsen TO, Ejlertsen B. The Prosigna 50-gene profile and responsiveness to adjuvant anthracycline-based chemotherapy in high-risk breast cancer patients. NPJ Breast Cancer. 2020 Feb 26;6:7. doi: 10.1038/s41523-020-0148-0. eCollection 2020. PMID: 32140564; PMCID: PMC7044229.
Copy Download .nbib Format: NLM
Correction: Gene expression profiling identifies FYN as an important molecule in tamoxifen resistance and a predictor of early recurrence in patients treated with endocrine therapy.

Oncogene

Elias D, Vever H, Lænkholm AV, Gjerstorff MF, Yde CW, Lykkesfeldt AE, Ditzel HJ.
PMID: 30242243
Oncogene. 2018 Oct;37(41):5585-5586. doi: 10.1038/s41388-018-0495-6.

Since the online publication of the above article, the authors have noted errors in subfigures 1c and 3b. Therefore, new images of the original immmunocytochemistry stainings have been obtained for Fig. 1c, and the Western blots for siRNA-mediated FYN...

Cite
Elias D, Vever H, Lænkholm AV, et al. Correction: Gene expression profiling identifies FYN as an important molecule in tamoxifen resistance and a predictor of early recurrence in patients treated with endocrine therapy. Oncogene. 2018;37(41):5585-5586doi: 10.1038/s41388-018-0495-6.
Elias, D., Vever, H., Lænkholm, A. V., Gjerstorff, M. F., Yde, C. W., Lykkesfeldt, A. E., & Ditzel, H. J. (2018). Correction: Gene expression profiling identifies FYN as an important molecule in tamoxifen resistance and a predictor of early recurrence in patients treated with endocrine therapy. Oncogene, 37(41), 5585-5586. https://doi.org/10.1038/s41388-018-0495-6
Elias, D, et al. "Correction: Gene expression profiling identifies FYN as an important molecule in tamoxifen resistance and a predictor of early recurrence in patients treated with endocrine therapy." Oncogene vol. 37,41 (2018): 5585-5586. doi: https://doi.org/10.1038/s41388-018-0495-6
Elias D, Vever H, Lænkholm AV, Gjerstorff MF, Yde CW, Lykkesfeldt AE, Ditzel HJ. Correction: Gene expression profiling identifies FYN as an important molecule in tamoxifen resistance and a predictor of early recurrence in patients treated with endocrine therapy. Oncogene. 2018 Oct;37(41):5585-5586. doi: 10.1038/s41388-018-0495-6. PMID: 30242243.
Copy Download .nbib Format: NLM
Tumour-infiltrating CD4-, CD8- and FOXP3-positive immune cells as predictive markers of mortality in BRCA1- and BRCA2-associated breast cancer.

British journal of cancer

Jørgensen N, Hviid TVF, Nielsen LB, Sønderstrup IMH, Eriksen JO, Ejlertsen B, Gerdes AM, Kruse TA, Thomassen M, Jensen MB, Lænkholm AV.
PMID: 34365471
Br J Cancer. 2021 Nov;125(10):1388-1398. doi: 10.1038/s41416-021-01514-7. Epub 2021 Aug 07.

BACKGROUND: The prognostic value of tumour-infiltrating lymphocytes (TILs) in breast cancer is well-established. However, the investigation of specific T-cell subsets exclusively in BRCA-associated breast cancer is sparse.METHODS: Tumour tissues from 414 BRCA-mutated breast cancer patients were analysed by immunohistochemistry...

Cite
Jørgensen N, Hviid TVF, Nielsen LB, et al. Tumour-infiltrating CD4-, CD8- and FOXP3-positive immune cells as predictive markers of mortality in BRCA1- and BRCA2-associated breast cancer. Br J Cancer. 2021;125(10):1388-1398doi: 10.1038/s41416-021-01514-7.
Jørgensen, N., Hviid, T. V. F., Nielsen, L. B., Sønderstrup, I. M. H., Eriksen, J. O., Ejlertsen, B., Gerdes, A. M., Kruse, T. A., Thomassen, M., Jensen, M. B., & Lænkholm, A. V. (2021). Tumour-infiltrating CD4-, CD8- and FOXP3-positive immune cells as predictive markers of mortality in BRCA1- and BRCA2-associated breast cancer. British journal of cancer, 125(10), 1388-1398. https://doi.org/10.1038/s41416-021-01514-7
Jørgensen, Nanna, et al. "Tumour-infiltrating CD4-, CD8- and FOXP3-positive immune cells as predictive markers of mortality in BRCA1- and BRCA2-associated breast cancer." British journal of cancer vol. 125,10 (2021): 1388-1398. doi: https://doi.org/10.1038/s41416-021-01514-7
Jørgensen N, Hviid TVF, Nielsen LB, Sønderstrup IMH, Eriksen JO, Ejlertsen B, Gerdes AM, Kruse TA, Thomassen M, Jensen MB, Lænkholm AV. Tumour-infiltrating CD4-, CD8- and FOXP3-positive immune cells as predictive markers of mortality in BRCA1- and BRCA2-associated breast cancer. Br J Cancer. 2021 Nov;125(10):1388-1398. doi: 10.1038/s41416-021-01514-7. Epub 2021 Aug 07. PMID: 34365471; PMCID: PMC8576013.
Copy Download .nbib Format: NLM
Syringomatous Tumour Presenting as Inversion of a Supernumerary Nipple.

Case reports in pathology

Öwall L, Mygind H, Rosenborg Å, Lænkholm AV.
PMID: 30792933
Case Rep Pathol. 2019 Jan 17;2019:9461815. doi: 10.1155/2019/9461815. eCollection 2019.

Syringomatous tumour (SyT) is a rare type of benign locally infiltrative tumour with debated origin. Because of the growth pattern, SyT can be mistaken for a malignant tumour, and it is therefore important to keep this diagnosis in mind....

Cite
Öwall L, Mygind H, Rosenborg Å, et al. Syringomatous Tumour Presenting as Inversion of a Supernumerary Nipple. Case Rep Pathol. 2019;2019:9461815doi: 10.1155/2019/9461815.
Öwall, L., Mygind, H., Rosenborg, �. �., & Lænkholm, A. V. (2019). Syringomatous Tumour Presenting as Inversion of a Supernumerary Nipple. Case reports in pathology, 20199461815. https://doi.org/10.1155/2019/9461815
Öwall, Louise, et al. "Syringomatous Tumour Presenting as Inversion of a Supernumerary Nipple." Case reports in pathology vol. 2019 (2019): 9461815. doi: https://doi.org/10.1155/2019/9461815
Öwall L, Mygind H, Rosenborg Å, Lænkholm AV. Syringomatous Tumour Presenting as Inversion of a Supernumerary Nipple. Case Rep Pathol. 2019 Jan 17;2019:9461815. doi: 10.1155/2019/9461815. eCollection 2019. PMID: 30792933; PMCID: PMC6354169.
Copy Download .nbib Format: NLM
Analytical validation of a standardized scoring protocol for Ki67: phase 3 of an international multicenter collaboration.

NPJ breast cancer

Leung SCY, Nielsen TO, Zabaglo L, Arun I, Badve SS, Bane AL, Bartlett JMS, Borgquist S, Chang MC, Dodson A, Enos RA, Fineberg S, Focke CM, Gao D, Gown AM, Grabau D, Gutierrez C, Hugh JC, Kos Z, Lænkholm AV, Lin MG, Mastropasqua MG, Moriya T, Nofech-Mozes S, Osborne CK, Penault-Llorca FM, Piper T, Sakatani T, Salgado R, Starczynski J, Viale G, Hayes DF, McShane LM, Dowsett M.
PMID: 28721378
NPJ Breast Cancer. 2016 May 18;2:16014. doi: 10.1038/npjbcancer.2016.14. eCollection 2016.

Pathological analysis of the nuclear proliferation biomarker Ki67 has multiple potential roles in breast and other cancers. However, clinical utility of the immunohistochemical (IHC) assay for Ki67 immunohistochemistry has been hampered by unacceptable between-laboratory analytical variability. The International Ki67...

Cite
Leung SCY, Nielsen TO, Zabaglo L, et al. Analytical validation of a standardized scoring protocol for Ki67: phase 3 of an international multicenter collaboration. NPJ Breast Cancer. 2016;2:16014doi: 10.1038/npjbcancer.2016.14.
Leung, S. C. Y., Nielsen, T. O., Zabaglo, L., Arun, I., Badve, S. S., Bane, A. L., Bartlett, J. M. S., Borgquist, S., Chang, M. C., Dodson, A., Enos, R. A., Fineberg, S., Focke, C. M., Gao, D., Gown, A. M., Grabau, D., Gutierrez, C., Hugh, J. C., Kos, Z., Lænkholm, A. V., Lin, M. G., Mastropasqua, M. G., Moriya, T., Nofech-Mozes, S., Osborne, C. K., Penault-Llorca, F. M., Piper, T., Sakatani, T., Salgado, R., Starczynski, J., Viale, G., Hayes, D. F., McShane, L. M., & Dowsett, M. (2016). Analytical validation of a standardized scoring protocol for Ki67: phase 3 of an international multicenter collaboration. NPJ breast cancer, 216014. https://doi.org/10.1038/npjbcancer.2016.14
Leung, Samuel C Y, et al. "Analytical validation of a standardized scoring protocol for Ki67: phase 3 of an international multicenter collaboration." NPJ breast cancer vol. 2 (2016): 16014. doi: https://doi.org/10.1038/npjbcancer.2016.14
Leung SCY, Nielsen TO, Zabaglo L, Arun I, Badve SS, Bane AL, Bartlett JMS, Borgquist S, Chang MC, Dodson A, Enos RA, Fineberg S, Focke CM, Gao D, Gown AM, Grabau D, Gutierrez C, Hugh JC, Kos Z, Lænkholm AV, Lin MG, Mastropasqua MG, Moriya T, Nofech-Mozes S, Osborne CK, Penault-Llorca FM, Piper T, Sakatani T, Salgado R, Starczynski J, Viale G, Hayes DF, McShane LM, Dowsett M. Analytical validation of a standardized scoring protocol for Ki67: phase 3 of an international multicenter collaboration. NPJ Breast Cancer. 2016 May 18;2:16014. doi: 10.1038/npjbcancer.2016.14. eCollection 2016. PMID: 28721378; PMCID: PMC5515324.
Copy Download .nbib Format: NLM
MCM3 upregulation confers endocrine resistance in breast cancer and is a predictive marker of diminished tamoxifen benefit.

NPJ breast cancer

Løkkegaard S, Elias D, Alves CL, Bennetzen MV, Lænkholm AV, Bak M, Gjerstorff MF, Johansen LE, Vever H, Bjerre C, Kirkegaard T, Nordenskjöld B, Fornander T, Stål O, Lindström LS, Esserman LJ, Lykkesfeldt AE, Andersen JS, Leth-Larsen R, Ditzel HJ.
PMID: 33398005
NPJ Breast Cancer. 2021 Jan 04;7(1):2. doi: 10.1038/s41523-020-00210-8.

Resistance to endocrine therapy in estrogen receptor-positive (ER

Cite
Løkkegaard S, Elias D, Alves CL, et al. MCM3 upregulation confers endocrine resistance in breast cancer and is a predictive marker of diminished tamoxifen benefit. NPJ Breast Cancer. 2021;7(1):2doi: 10.1038/s41523-020-00210-8.
Løkkegaard, S., Elias, D., Alves, C. L., Bennetzen, M. V., Lænkholm, A. V., Bak, M., Gjerstorff, M. F., Johansen, L. E., Vever, H., Bjerre, C., Kirkegaard, T., Nordenskjöld, B., Fornander, T., Stål, O., Lindström, L. S., Esserman, L. J., Lykkesfeldt, A. E., Andersen, J. S., Leth-Larsen, R., & Ditzel, H. J. (2021). MCM3 upregulation confers endocrine resistance in breast cancer and is a predictive marker of diminished tamoxifen benefit. NPJ breast cancer, 7(1), 2. https://doi.org/10.1038/s41523-020-00210-8
Løkkegaard, Sanne, et al. "MCM3 upregulation confers endocrine resistance in breast cancer and is a predictive marker of diminished tamoxifen benefit." NPJ breast cancer vol. 7,1 (2021): 2. doi: https://doi.org/10.1038/s41523-020-00210-8
Løkkegaard S, Elias D, Alves CL, Bennetzen MV, Lænkholm AV, Bak M, Gjerstorff MF, Johansen LE, Vever H, Bjerre C, Kirkegaard T, Nordenskjöld B, Fornander T, Stål O, Lindström LS, Esserman LJ, Lykkesfeldt AE, Andersen JS, Leth-Larsen R, Ditzel HJ. MCM3 upregulation confers endocrine resistance in breast cancer and is a predictive marker of diminished tamoxifen benefit. NPJ Breast Cancer. 2021 Jan 04;7(1):2. doi: 10.1038/s41523-020-00210-8. PMID: 33398005; PMCID: PMC7782683.
Copy Download .nbib Format: NLM
Showing 1 to 11 of 11 entries